Precision IO Group Launches U.S. Clinical Study for Epione® Robotic System
Precision IO Group has launched a U.S. clinical study named EPIOS to evaluate the safety and performance of the Epione® robotic platform, aimed at treating bone tumors and metastases. The study’s goal is to facilitate the expansion of Epione’s market approvals in the U.S., with the first patient treated on April 28, 2026, at a prominent cancer center in Miami, Florida. The device has already received CE marking for bone indications.
MIAMI–(BUSINESS WIRE)–Precision IO Group, the parent company of Quantum Surgical, announced the launch of EPIOS, a new U.S. clinical study evaluating the safety and performance of the Epione® robotic platform for the treatment of bone tumors and metastases. The study is designed to support the expansion of Epione’s market approvals in the United States. The first patient was treated on April 28, 2026, in a leading cancer center based in Miami, Florida. Epione has been CE marked for bone indic